Developing antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology.
Employees: 11-50
Total raised: $50M
Founded date: 2022
Investors 1
| Date | Name | Website |
| - | Mission Bi... | missionbio... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.03.2023 | Series A | $50M | Mubadala C... |
Mentions in press and media 4
| Date | Title | Description | Source |
| 22.03.2023 | EpiBiologics Raises $50M in Series A Financing | EpiBiologics, a San Mateo, CA-based biotechnology company building a next-generation antibody-based ... | finsmes.co... |
| 22.03.2023 | EpiBiologics Launches with $50M Series A Financing | SAN MATEO, CA, EpiBiologics launches with $50 million in Series A funding led by Mubadala Capital ... | vcnewsdail... |
| - | EpiBiologics | “EpiBiologics” | fastfounde... |
| - | EpiBiologics: Protein Degradation Platform Company Closes Ov... | EpiBiologics – a biotechnology company advancing a next-generation antibody-based protein degradatio... | pulse2.com... |